MEK Inhibitor Compounds with Optimized Bioavailability and CNS Selectivity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current MEK inhibitors for cancer treatment have limitations in terms of potency, oral bioavailability, half-life, and CNS penetration, leading to potential side effects and reduced efficacy, and there is a need for compounds that can effectively target MEK1 and MEK2 to treat various diseases including cancer, inflammation, and hyperproliferative disorders.
Innovation Solution
Development of specific compounds, such as those represented by Formulas (I) and (II), which are MEK enzyme inhibitors with improved pharmacological properties like high oral bioavailability and longer half-life, and low brain barrier penetration, designed to treat hyperproliferative disorders, inflammation, and other diseases modulated by the MEK cascade.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current MEK inhibitors are used for cancer treatment, then MEK enzyme inhibition is achieved, but potency, oral bioavailability, and half-life are limited
Solution Approach 1:
The patent applies parameter changes by systematically modifying chemical structures (Formulas I and II) including substituent groups (R1-R6, X, Y, Z) and molecular properties to optimize the balance between MEK inhibition potency and oral bioavailability. This involves changing physical and chemical parameters of the inhibitor molecules to achieve improved pharmacological properties while maintaining target engagement.
2Reliability
If current MEK inhibitors are used, then MEK pathway inhibition is achieved, but half-life is limited requiring frequent dosing
Solution Approach 1:
The patent employs parameter changes by modifying molecular structure parameters (substituent groups, molecular weight, lipophilicity) to extend the half-life of MEK inhibitors. The chemical structures in Formulas I and II are designed with specific substituent patterns that enhance metabolic stability and prolong duration of action, allowing for less frequent dosing while maintaining therapeutic efficacy.
3Reliability
If MEK inhibitors with high potency are developed, then cancer treatment efficacy is improved, but CNS penetration may increase causing side effects
Solution Approach 1:
The patent applies local quality by designing MEK inhibitors with specific molecular properties that create localized effects in peripheral tissues while minimizing CNS penetration. The chemical structures (Formulas I and II) are engineered with substituent groups that provide high potency at the MEK target in peripheral compartments while maintaining low blood-brain barrier permeability, thus achieving tissue-selective action that spares the CNS.
4Reliability
If MEK inhibitors are designed for high selectivity, then off-target effects are reduced, but pharmacological properties such as oral bioavailability may be compromised
Solution Approach 1:
The patent resolves this contradiction through parameter changes by systematically optimizing multiple molecular parameters simultaneously. The chemical structures in Formulas I and II incorporate specific substituent combinations that maintain high MEK selectivity through precise molecular recognition while adjusting other parameters (solubility, permeability, metabolic stability) to ensure adequate oral bioavailability. This multi-parameter optimization allows both selectivity and bioavailability to be satisfied.
Data Source
AI summary
The invention pertains to compound of Formula (I) wherein X, Y, Z, R1, R2, R3, R4, A and A′ are as described hereinabove. Formula (I) and (II) compounds can be used in pharmaceutical compositions, useful for the treatment of diseases.